Federal prosecutors reject $1 billion J & J settlement
Government prosecutors rejected a proposed settlement worth roughly $1 billion with pharmaceutical giant Johnson & Johnson over questionable marketing tactics for the antipsychotic Risperdal.
Department of Justice prosecutors, who were tasked with approving a settlement brokered by federal prosecutors in Philadelphia, rejected the settlement because it was not large enough, the Wall Street Journal reported.
The antipsychotic medication is often prescribed off-label to treat aggressive behaviors of elderly nursing home residents with dementia.
The department also is seeking a settlement $1.4 billion from Eli Lilly over its antipsychotic Zyprexa, the newspaper reported.